6,137 Shares in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Purchased by WCM Investment Management LLC

WCM Investment Management LLC purchased a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 6,137 shares of the biotechnology company's stock, valued at approximately $600,000.

A number of other hedge funds have also made changes to their positions in SRPT. PNC Financial Services Group Inc. lifted its holdings in shares of Sarepta Therapeutics by 189.1% in the 1st quarter. PNC Financial Services Group Inc. now owns 5,784 shares of the biotechnology company's stock valued at $452,000 after buying an additional 3,783 shares during the period. Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in shares of Sarepta Therapeutics in the first quarter valued at $185,000. MetLife Investment Management LLC purchased a new stake in shares of Sarepta Therapeutics in the first quarter valued at $421,000. Great West Life Assurance Co. Can grew its position in shares of Sarepta Therapeutics by 6.6% in the first quarter. Great West Life Assurance Co. Can now owns 4,541 shares of the biotechnology company's stock valued at $377,000 after purchasing an additional 281 shares during the period. Finally, Dimensional Fund Advisors LP grew its position in shares of Sarepta Therapeutics by 12.3% in the first quarter. Dimensional Fund Advisors LP now owns 179,294 shares of the biotechnology company's stock valued at $14,007,000 after purchasing an additional 19,660 shares during the period. Hedge funds and other institutional investors own 86.68% of the company's stock.

Insider Buying and Selling

In related news, Director Kathryn Jean Boor sold 761 shares of the business's stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $122.93, for a total transaction of $93,549.73. Following the transaction, the director now directly owns 7,516 shares in the company, valued at $923,941.88. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, Director Kathryn Jean Boor sold 761 shares of the business's stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $122.93, for a total transaction of $93,549.73. Following the completion of the transaction, the director now owns 7,516 shares of the company's stock, valued at $923,941.88. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Bilal Arif sold 2,000 shares of the company's stock in a transaction on Friday, March 1st. The shares were sold at an average price of $128.84, for a total transaction of $257,680.00. Following the completion of the sale, the insider now directly owns 26,836 shares of the company's stock, valued at approximately $3,457,550.24. The disclosure for this sale can be found here. Insiders sold 22,096 shares of company stock valued at $2,739,419 over the last quarter. Insiders own 7.40% of the company's stock.

Sarepta Therapeutics Stock Down 3.7 %

NASDAQ SRPT traded down $4.56 on Monday, reaching $118.31. The company had a trading volume of 860,425 shares, compared to its average volume of 1,008,528. The company's fifty day moving average is $127.31 and its 200-day moving average is $110.37. The company has a debt-to-equity ratio of 1.32, a quick ratio of 3.45 and a current ratio of 3.95. Sarepta Therapeutics, Inc. has a 1-year low of $55.25 and a 1-year high of $159.89. The firm has a market capitalization of $11.11 billion, a price-to-earnings ratio of -19.33 and a beta of 0.94.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its quarterly earnings results on Wednesday, February 28th. The biotechnology company reported $0.47 earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.50. The firm had revenue of $396.80 million for the quarter, compared to analysts' expectations of $387.18 million. Sarepta Therapeutics had a negative net margin of 43.11% and a negative return on equity of 18.97%. The business's revenue was up 53.6% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.24) EPS. On average, research analysts forecast that Sarepta Therapeutics, Inc. will post 2.14 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Needham & Company LLC reduced their price objective on Sarepta Therapeutics from $169.00 to $166.00 and set a "buy" rating on the stock in a research note on Thursday, February 29th. Mizuho upped their target price on Sarepta Therapeutics from $130.00 to $145.00 and gave the company a "buy" rating in a report on Wednesday, February 14th. UBS Group upped their target price on Sarepta Therapeutics from $164.00 to $167.00 and gave the stock a "buy" rating in a research report on Friday, March 1st. Royal Bank of Canada increased their price objective on Sarepta Therapeutics from $151.00 to $157.00 and gave the company an "outperform" rating in a research report on Thursday, February 29th. Finally, Evercore ISI upped their price target on shares of Sarepta Therapeutics from $108.00 to $138.00 and gave the stock an "in-line" rating in a research note on Tuesday, February 20th. Four equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $158.38.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.